Ann: Trading Halt, page-57

Read this segment of company announcement very carefully.
Markets always over react on both the sides.

While the Cosette Notice asserts that a Mayne Material Adverse Change has occurred, it does not
constitute a notice of termination of the SID. Cosette has indicated to Mayne Pharma that based
on its view that a Mayne Material Adverse Change has occurred, the parties’ consultation
obligations under the SID are enlivened and that Cosette intends to comply with them. Cosette
has also indicated that if the consultation process does not achieve a satisfactory outcome for
Cosette, it intends to issue a notice to terminate the SID at the end of the consultation period.
Mayne Pharma has communicated to Cosette its view that there is no obligation at this stage for
the parties to consult under the SID, given that Mayne Pharma has rejected Cosette’s contention
that there has been any Mayne Material Adverse Change. However, Mayne Pharma remains open
to engaging in dialogue with Cosette with a view to resolving the matters raised by Cosette.
As mentioned above, Mayne Pharma has formally responded to the Cosette Notice and has firmly
rejected the matters asserted in it. Mayne Pharma has reminded Cosette of its obligations under
the SID and has informed Cosette that the parties are obliged to proceed to progress the Scheme
in accordance with the timetable for so long as the SID has not been terminated. As a
consequence, Mayne Pharma will continue to provide Cosette with information under the terms
of the SID as required, and will otherwise continue to take steps to implement the proposed
transaction contemplated by the SID in accordance with the timetable. Mayne Pharma has
reserved all of its rights in connection with any failure by Cosette to perform its obligations under
the SID and intends to enforce its rights under the SID.